ReviewCNS & neurological disorders drug targets2011
Immunotherapy for drug abuse.
Review in CNS & neurological disorders drug targets, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Vaccines as a preventive tool for substance use disorder: A systematic review including a meta-analysis on nicotine vaccines' immunogenicity.Human vaccines & immunotherapeutics · 2022Pooled it
- AI-based IsAb2.0 for antibody design.Briefings in bioinformatics · 2024Article
- Immunotherapy as a treatment to confront the ongoing opioid epidemic- A review.Journal of cellular and molecular immunology · 2022Article
- IsAb: a computational protocol for antibody design.Briefings in bioinformatics · 2021Article
- Biologic Approaches to Treat Substance-Use Disorders.Trends in pharmacological sciences · 2015Review
- Current approaches for the discovery of drugs that deter substance and drug abuse.Expert opinion on drug discovery · 2014Review
- A human recombinant monoclonal antibody to cocaine: Preparation, characterization and behavioral studies.Bioorganic & medicinal chemistry letters · 2014Article
- A methamphetamine vaccine attenuates methamphetamine-induced disruptions in thermoregulation and activity in rats.Biological psychiatry · 2013Article
- Prospects, promise and problems on the road to effective vaccines and related therapies for substance abuse.Expert review of vaccines · 2013Review
- The neurocircuitry of illicit psychostimulant addiction: acute and chronic effects in humans.Substance abuse and rehabilitation · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Substance use disorders continue to be major medical and social problems worldwide. Current medications for substance use disorders have many limitations such as cost, availability, medication compliance, dependence, diversion of some to illicit use and relapse to addiction after discontinuing their use. Immunotherapies using either passive monoclonal antibodies or active vaccines have distinctly different mechanisms and therapeutic utility from small molecule approaches to treatment. They have great potential to help the patient achieve and sustain abstinence and have fewer of the above limitations. This review covers the cocaine vaccine development in detail and provides an overview of directions for developing anti-addiction vaccines against the abuse of other substances. The notable success of the first placebo-controlled clinical trial of a cocaine vaccine, TA-CD, has led to an ongoing multi-site, Phase IIb clinical trial in 300 subjects. The results from these trials are encouarging further development of the cocaine vacine as one of the first anti-addiction vaccines to go forward to the U.S. Food and Drug Administration for review and approval for human use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.